Annual Report to Shareholders
Released
Released
Announcement PDF
Annual Report
Financial Report for the year ended 30 June 2024
Microba Life Sciences Limited
and controlled entities
Microba Life Sciences Limited | ABN 82 617 096 652
Corporate
Directory
Directors
Pasquale Rombola
Ian Frazer
Gene Tyson
Richard Bund
Hyungtae Kim
Jacqueline Fernley
Key management
Luke Reid (Chief Executive Officer)
personnel
James Heath (Chief Financial Officer)
Company secretaries
James Heath
Peter Webse
Registered office and
Microba Life Sciences Limited
principal place of business
Level 10
324 Queen Street
Brisbane QLD
Australia
Share register
Automic Pty Ltd
Level 35
477 Collins Street
Melbourne VIC
Australia
Auditor
Pitcher Partners
Level 38
345 Queen Street
Brisbane QLD
Australia
Solicitors
Thomson Geer
Level 28
1 Eagle Street
Brisbane QLD
Australia
Stock exchange listing
Microba Life Sciences Limited shares are listed on the Australian
Securities Exchange (ASX code: MAP)
Website
www.microba.com
Corporate
The Company’s corporate governance statement is located at the
Governance Statement
Company’s website: https://ir.microba.com/shareholderinformation
Annual Report 2024
4
Table of
Contents
Performance Highlights
06
Chair, Deputy Chair & CEO Letter
07
Financial Review
10
Review of Operations & Activities
13
Diagnostics – Personal Testing
15
Services – Research Testing
17
Therapeutics
18
Material Business Risks
21
Directors’ Report
24
Financial Statements
39
ASX Additional Information
86
Annual Report 2024
5
Performance
Highlights
$12.09m
Strong year-on-year growth
•
FY24 revenue of $12.09m delivering 123.1% growth on the prior financial
year with Personal Testing & Supplements up 207.8% to $9.46m and
Research Testing up 12% to $2.63m
•
Cash receipts totalling $12.48m, representing 96.3% growth on the prior year
•
Successful acquisition of United Kingdom microbiome company, Invivo
Clinical which is delivering results aligned to expectations, generating
$4.29m in sales for H2 FY24
•
Gastrointestinal Disorder Test, MetaXplore™ grew strongly during FY24
with test sales growing 385% year-on-year since launch in February 2023
•
Gastrointestinal Pathogen Test, MetaPanel™, launched nationwide in
Australia with Sonic Healthcare (ASX: SHL) with sales building across all
major states of the Australia
Successful completion of Phase 1 clinical trial for MAP 315,
preparing for Phase 2
•
Completed on schedule, demonstrating MAP 315 is safe and well tolerated
at both low and high doses
•
Preparation for Phase 2 well advanced
Successful completion of world-first autoimmune
therapeutics discovery program with Ginkgo Bioworks
•
Generating new therapeutic intellectual property assets with 6 lead strains
demonstrating compelling disease relevant activity
Additional achievements
$20.89m
Annual Report 2024
•
Animal model data and immunological data confirm anti-tumour activity
for leads in Immuno-Oncology therapeutic discovery program, and clinical
data and sample set grown to >3,500 patients
•
Second Agreement executed with IFF (NYSE: IFF) to develop novel
microbiome-based treatments for multiple forms of Allergy
Company is well funded
•
$20.89 million in cash or equivalents at 30 June 2024
•
Approximately $6.0m expected from Microba’s FY24 R&D Tax Incentive,
expected to be received in H1 FY25
6
01
Chair,
Deputy Chair
& CEO Letter
Annual Report 2024
7
Message from the Chair,
Deputy Chair & CEO
Dear Shareholders,
We remain steadfast in our belief that the human gut microbiome represents one of the biggest untapped
opportunities to improve human health, and that microbiome testing and therapeutics will become a routine
part of healthcare.
After many years of dedicated effort, we are witnessing the realisation of this vision.
The formative years were focused on delivering immediate value from our world-leading technology
through the delivery of non-diagnostic personal and research testing services and early revenues, which
enabled us to build the world’s most valuable microbiome databank.
After many years of research and development interrogating that databank, Microba has evolved into a
medical diagnostics company delivering the clinical value of microbiome testing, and a clinical-stage drug
development company at the forefront of microbiome-based therapeutic development.
Microba’s work in microbiome diagnostics, now has the company positioned with two novel diagnostic tests
assisting patients with unresolved gastrointestinal symptoms, a condition which impacts over 37m people in
the US alone with almost 50% of those individuals not having resolution through the current standard of care.
Earlier this year we launched MetaPanel for diagnosing gastrointestinal infections nationwide in Australia
together with major shareholder and partner Sonic Healthcare (ASX: SHL). Real world data to date show
that we can achieve new answers for 24% of individuals using that test. When a pathogenic cause of a
patient’s symptoms is ruled out, MetaXplore, which was launched in Australia in late FY23, is designed to
identify functional causes for non-pathogenic GI symptoms. Our real-world data show that today we can
identify new management opportunities for a further 28% of patients using this test. Together, our advanced
microbiome diagnostics are positioned to transform the standard of care for the millions of patients across
the globe suffering with unresolved gastrointestinal symptoms.
Our priority international markets for these tests are the United Kingdom and United States. Aligned to
this, we strategically accelerated our United Kingdom commercialisation plan this year with the successful
acquisition of leading United Kingdom microbiome testing company, Invivo Clinical. Through that
acquisition we acquired a strong team and established base of over 1,700 active healthcare professionals,
who are delivering revenues aligned to expectation, and we are now preparing to launch our MetaXplore
test in the UK.
Microba’s work in microbiome therapeutics, leveraging the company’s data-driven therapeutic platform,
now has the company positioned with a lead candidate preparing to advance into a Phase 2 efficacy trial
and a compelling pipeline of pre-clinical leads to address major unmet needs across inflammatory bowel
disease, oncology and autoimmune disease.
Following release of the first two FDA approved drugs addressing infectious disease (C.difficile infection),
pharma companies and the sector as a whole are watching to see clinical efficacy demonstrated in a
chronic disease setting, with the most advanced programs across microbiome drug developers targeting
inflammatory bowel disease, immuno-oncology, and Graft Versus Host Disease (GVHD). With successful
completion of the Phase 1 clinical trial for lead candidate MAP 315 under Microba’s Inflammatory Bowel
Disease program, Microba is in a unique position to advance towards a fully powered Phase 2 efficacy
Annual Report 2024
8
Message from the Chair,
Deputy Chair & CEO
study for a live biotherapeutic in a chronic disease setting. This stands to be a critical milestone for the
microbiome drug development sector through demonstration of efficacy in Inflammatory Bowel Disease.
In addition, promising intellectual property was generated for Microba’s Autoimmune Disease and
Immuno-Oncology programs. The drug discovery program with Ginkgo Bioworks was a world first effort,
generating over 3 million data points and delivering 6 compelling leads. Our therapeutic advancements
continue to validate Microba’s unique ability to discover therapeutically active biology from the human
microbiome through the company’s data-driven Therapeutics Platform. Microba continues to engage
with global pharmaceutical and biotechnology companies, and our strategy remains to partner or transact
on our therapeutic assets at the appropriate time, to maximise value for shareholders. Through Microba’s
therapeutic programs and pipeline of assets, we are excited about the impact the company’s products can
have on individuals suffering from chronic diseases, and the commercial opportunity for shareholders.
Following another year of growth and advancement in FY24, we now look toward FY25, and anticipate a
robust year of accelerating growth for Microba’s diagnostic testing products and the advancement of our
therapeutic programs and assets.
On behalf of the Board of Directors and all stakeholders at Microba, we would like to say thank you for your
continuing support. We are proud of the impact Microba is delivering today, and we are excited about the
future impact of our products for those suffering from chronic diseases.
We extend our sincere thanks and appreciation to the entire Microba team, our scientists, collaborators, and
partners around the world.
Mr. Pasquale Rombola
Prof. Ian Frazer (AC)
Dr. Luke Reid
CHAIR
DEPUTY CHAIR
CHIEF EXECUTIVE OFFICER
Annual Report 2024
9
02
Financial
Review
Annual Report 2024
10
Financial
Review
The financial year ending June 2024 has been a period of significant revenue
growth supported by product and geographical expansion. Throughout FY24
the company continued to progress its world leading microbiome diagnostic test
portfolio, as well as making positive advancements across its three therapeutic
programs. All of these milestones were achieved whilst maintaining disciplined
financial management across the Microba group.
Revenue for the financial year totalled $12.09m,
Following the acquisition on 5 December 2023,
representing 123.1% growth on the prior financial
Invivo Clinical generated $4.85 million in revenue
year. Cash receipts for the full financial year
for the partial year ended 30 June 2024. This UK
totalled $12.48m. This growth was primarily driven
derived revenue was driven by the sale of over
by Revenue from the Company’s Testing Services
6,600 microbiome tests across gut, vaginal, oral,
& Supplements business unit which accelerated
and urinary testing, as well as more than 125,000
its year-on-year organic growth in addition to the
units of Invivo branded and third party licensed
revenue added from Invivo Clinical. In FY24 revenue
nutritional supplements.
for this business unit was up 207.8% to $9.46m from
$3.07m. The Research Services division of the Testing
Services & Supplements business unit delivered
$2.63m in revenue, up 12% on the prior year.
The financial year’s revenue growth was again
weighted to the second half as the company
continues to grow, and we anticipate this growth
trend to continue into FY25 as the Company
This growth was supported by a growing recognition
continues to grow through the year in its
of the critical role that the microbiome plays in
selected markets.
health and disease, coupled with a rising demand
for personalised healthcare solutions. Interest
has increased within the healthcare practitioner
community led by the growing clinical literature,
awareness and education, leading to increased test
referrals to patients to deliver more informed clinical
decisions and better personalised care. Additionally,
ongoing research and media coverage have
reinforced the importance of microbiome health,
further driving patient engagement and the adoption
of our diagnostic testing services.
During FY24, the Group sustained a healthy
gross margin of 49%, consistent with the
previous financial year. This achievement
came despite inflationary pressures on key
inputs to Cost of Sales, particularly laboratory
consumables. The Group successfully maintained
margins by enhancing the efficiency of laboratory
processes, handling higher sample volumes
than the prior year, which unlocked economies
of scale, and benefiting from a more favourable
revenue mix with higher-margin products. The
FY24 revenue growth was bolstered by positive
Group remains focussed on sustaining a positive
market traction for the recently launched
gross margin in the coming financial year. Our
healthcare practitioner only MetaXplore™
focus will be on further optimising laboratory
gastrointestinal disorders test. This growth was
processes, reducing sequencing costs through a
reflected in clinician adoption numbers, high
planned upgrade to the industry leading Illumina
customer retention, repeat test referrals, and
NovaSeqX Plus DNA sequencing platform, and
the onboarding of new ordering clinicians.
unlocking additional economies of scale to drive
MetaXplore™ sales grew by 60% in H2 FY24
continued margin improvements.
compared to H1 FY24, with over 700 Australian
clinicians having ordered a test by the end of FY24.
Annual Report 2024
11
Financial
Review
Microba Revenue - YoY Growth
14.000,000
12.000,000
10.000,000
8.000,000
6.000,000
4.000,000
2.000,000
-
FY18
FY20
FY19
Research Services
FY21
Microba Personal Testing
FY22
FY23
FY24
Invivo Clinical (UK)
Microba continued to invest in its therapeutics
of UK microbiome leader, Invivo Clinical. The
and diagnostic product development. This
acquisition was completed on 5 December 2023.
included over $13m of investment in research &
Invivo Clinical was acquired for approximately
development activities principally related to the
$13.35m, and there is up to approximately $8.58
Company’s therapeutic development programs.
million in earn-out consideration tied to revenue
Microba reported a loss for the year ended 30
growth hurdles, which is payable in both cash and
June 2024 of $18.36m compared with a loss of
ordinary Microba shares.
$12.68m in FY23, noting that FY24 saw a significant
increase in activity across the group including the
completion of a Phase 1 trial in IBD, completion of
the Autoimmune program with Ginkgo Bioworks,
the launch of MetaPanel with Sonic Healthcare
and the acquisition of UK microbiome leader,
Invivo Clinical.
The Company’s Net Assets improved by 6.85%,
compared with the previous year (up $2.64m
to, $41.22m, this position was driven by a large
increase in the Groups Intangible Assets ($21.88m,
up $19.03m from $2.8m in the prior year) related to
the Invivo Clinical acquisition. These movements
were offset by movements in the Group’s liabilities
As at 30 June 2024, Microba had $20.89 million
which included a deferred tax liability ($1.56m) and
in cash or equivalents with minimal debt. This
contingent consideration ($2.32m current liability
strong liquidity position supports the Group’s
and $1.83m non-current liability) associated with
continued operations and growth initiatives. This
the Invivo Clinical acquisition. Contract liabilities,
cash balance was reinforced by a capital raising
relating to deferred revenue increased $0.88m from
completed during the FY24 year whereby the
$1.30m to $2.18m as a result of a higher volume of
Company raised $20m to fund the acquisition
customer sales during the year.
Annual Report 2024
12
03
Review of
Operations
& Activities
Annual Report 2024
13
Review of Operations & Activities
World leading microbiome
analysis technology
Proprietary databank
Advanced AI and biostatistics
powering a diagnostics and
therapeutics platform
Testing Business
Therapeutics Business
Next generation gastrointestinal diagnostics
Precision microbiome therapeutics
2 clinical tests.
Data driven therapeutic development platform.
GASTROINTESTINAL
PATHOGEN TEST
GASTROINTESTINAL
DISORDERS TEST
ADVANCED AI/
ML APPROACH
UNDERPINNED BY
WORLD LEADING
TECHNOLOGY
2 channels to market.
PATHOLOGY PARTNER
CHANNEL
DIRECT TO PRACTITIONER
CHANNEL
3 therapeutic programs.
INFLAMMATORY
BOWEL DISEASE
PROGRAM
IMMUNOONCOLOGY
PROGRAM
AUTOIMMUNE
DISEASE
PROGRAM
CLINICAL
INDICATION
CLINICAL
INDICATION
CLINICAL
INDICATION
Mild-moderate
Ulcerative Colitis
Multiple cancers to
enhance checkpoint inhibitor
treatment response
Lupus, psoriatic
arthritis &
autoimmune liver
disease
DEVELOPMENT
STAGE
DEVELOPMENT
STAGE
Pre-clinical. Lead
candidate selection
Pre-clinical
PRIMARY TARGET CLINICIANS
PRIMARY TARGET CLINICIANS
Gastroenterologists
General Practitioners
Integrative General
Practitioners
DEVELOPMENT
STAGE
Other Specialists
Integrative Specialists
Phase 1 Complete
Dieticians
Phase 2 Readiness
Nutritionists
Naturopathic practitioners
Annual Report 2024
NOVEL PIPELINE
OF MICROBIOME
THERAPIES - POTENT,
ORAL DELIVERY, SAFE
& MANUFACTURABLE
14
Review of Operations & Activities
DIAGNOSTICS
Personal Testing
Diagnostic testing products advancing the management of gastrointestinal disease
MetaXplore – Gastrointestinal Disorder Test
In February 2023, Microba launched the MetaXplore™ test to healthcare practitioners, which offers the most
comprehensive gastrointestinal testing solution for identifying functional causes of non-pathogenic GI symptoms.
Since launch over 700 clinicians have now ordered the test across Australia, generating over 5,800 test sales
with strong half on half growth in both MetaXplore™ test sales volume and MetaXplore™ ordering clinicians.
>5,800
2,935
>700
723
Tests sold since March 2023
Clinicians have ordered at 30 June 2024
60%
65%
Growth HoH
Growth HoH
1,841
436
984
181
H2 FY23
H1 FY24
H2 FY24
MetaXplore test sales volume
H2 FY23
H1 FY24
H2 FY24
MetaXplore ordering clinicians
Table 1 – MetaXplore’s strong growth profile
MetaXplore™ is the most comprehensive test available to support diagnosis and management of functional
gastrointestinal disorders. Over 30% of the population suffer from a functional gastrointestinal disorder, also
known as a disorder of gut-brain interaction (DGBI) related to the bowel 1. Real world data demonstrates that
28% of patients tested with MetaXplore get new information and direction what would have previously gone
unidentified2. It is estimated that total addressable market for the MetaXplore test in the United States alone
is over US $9.5B3.
Annual Report 2024
15
Review of Operations & Activities
DIAGNOSTICS
During the financial year, Microba dedicated substantial effort and focus into enhancing and refining the
MetaXplore™ test to maximise clinical utility and outcomes for clinicians and patients. This involved the
rollout of several new features as part of a product roadmap designed to lead the clinical utility and rapidly
interpretability of microbiome testing.
MetaPanel – Gastrointestinal Pathogen Test
In March 2024, Microba launched the MetaPanel™ test to healthcare professionals, which delivers the most
comprehensive gastrointestinal testing solution for detecting pathogens that cause GI symptoms. Microba
launched the test nationwide in Australia together with the Group’s largest shareholder and partner Sonic
Healthcare (ASX: SHL). Successful launch education events have been held together with Sonic Healthcare
across New South Wales, Victoria, Queensland, South Australia, Australian Capital Territory and Tasmania.
Doctor referrals and sales continue to grow monthly across the country, focused around the major
east coast states New South Wales, Victoria and Queensland. The sales strategy is focused on engaging
gastroenterology specialists and general practitioners (GPs).
MetaPanel™ is a world-first NATA accredited test for diagnosing gastrointestinal pathogens. It is the most
comprehensive gastrointestinal pathogen test available, detecting both common and difficult-to-identify
pathogens capable of causing serious infection. Real world data demonstrates that 24% of patients tested with
MetaPanel™ get a diagnosis that would have been undiagnosed or experienced delayed time to diagnosis and
resolution4. It is estimated that total global addressable market for the MetaPanel test is over US $9B5.
International expansion into the United Kingdom
with strategic acquisition
Microba acquired 100% of the issued share capital in UK registered company, Invivo Clinical Limited (Invivo)
on December 5, 2023. Financial and corporate integration has been completed with the first full half of
Invivo sales and revenue as part of the Microba group delivering in line with expectations, generating
$4.85m for the half year of ownership. To unlock the first phase of growth over the coming financial year,
Microba has invested selectively to unlock latent growth potential within the existing Invivo business by
bolstering Invivo’s sales and marketing team resourcing. For the second stage of growth targeting the core
growth synergy, the Company is preparing to launch Microba’s MetaXplore™ testing in FY25 to Invivo’s over
7,000 clinician customer base.
The UK is a key market in the next phase of Microba’s international growth strategy. Invivo is a pioneer in
microbiome testing for healthcare professionals in the United Kingdom. Acquiring a market leading position,
customer and geographical base in the UK through Invivo Clinical, together with Microba’s Sonic Healthcare
partnership, provides deep access to the entire UK healthcare market spanning private practice and the
public NHS environment.
Annual Report 2024
16
Review of Operations & Activities
SERVICES
Research Testing
Advancing global microbiome research
With Microba’s world-leading technologies and
expertise, the company continues to work with
leading universities and research institutes, as well as
biotechnology, pharmaceutical and food companies.
multistage research program between the parties
to develop novel microbiome-based treatments
for multiple forms of allergy. The Research
Agreement marks the second agreement between
Microba and IFF, which is a follow up to the initial
research services agreement executed on 9
Microba delivered over $2.6m in research
November 2021. Under the Initial Agreement, for
projects across the year and is extremely proud
Stage 1, Microba completed the identification of
of the impact it is making through working
lead species from which IFF was entitled to select
with a diverse array of customers and partners
strains under the Initial Agreement. The Stage 2
to advance the global knowledge base using
project is to complete the successful isolation of
Microba’s precision tools.
strains selected from Stage 1 and characterisation
of those strains. Microba continues to grow this
During the year Microba signed a further research
long-term commercial relationship between the
agreement with International Flavors and
parties, to develop novel allergy treatments.
Fragrances IFF (NYSE: IFF) as part of an ongoing
Annual Report 2024
17
Review of Operations & Activities
THERAPEUTICS
Using the company’s human first data-driven Therapeutics Platform, significant
progress was made across Microba’s therapeutic programs.
Inflammatory Bowel Disease Program –
MAP 315 is being developed for the treatment of
Successful Phase 1 trial, preparing for Phase 2
UC, a debilitating form of Inflammatory Bowel
In December 2023, the Phase 1 clinical trial of
lead drug candidate MAP 315 was completed on
schedule, the trial demonstrated that MAP 315 is
safe and well tolerated at both low and high doses.
Pre-clinical characterisation data, supports
the core mechanisms of action for MAP 315
stimulating mucosal healing (modulation of WNT
signalling pathway, restoration of gut barrier
integrity) and immune homeostasis (induction of
regulatory T cells), both central to the aetiology
and pathophysiology of Ulcerative Colitis (UC). The
pre-clinical data together with the Phase 1 clinical
study results provide strong positive support for
continuing to advance the clinical development of
MAP 315 for the treatment of Ulcerative Colitis.
Disease (IBD) with more than 50% of patients
unable to achieve sustained remission with current
standard of care. The market for UC treatment was
valued at US$7.5b in 2020 and is forecast to grow
to US$10.8b by 20306.
Microba’s novel drug candidate MAP 315 was
originally identified using the Company’s datadriven Therapeutic Platform, demonstrating that
this previously unidentified novel bacterial species
is commonly observed in healthy individuals
but consistently deficient in individuals with IBD,
and in particular UC. Subsequent pre-clinical
investigation of MAP 315 through both in vitro
and in vivo models demonstrated that MAP 315
promotes epithelial restitution and mucosal
healing – biological activities that are associated
The preparation for a Phase 2 trial is well
with disease remission but not adequately
advanced, including regulatory and manufacturing
addressed through existing therapies. MAP 315
(CMC). The Microba Therapeutics team are
provides a compelling commercial opportunity
continuing to bolster the CMC package in support
to fill a key gap in the current standard of care for
of at scale GMP manufacturing, finalisation of the
UC treatment and represents a potential novel
regulatory documentation and achieving readiness
treatment paradigm for patients living with this
for an investigational new drug (IND) submission.
debilitating disease.
Annual Report 2024
18
Review of Operations & Activities
THERAPEUTICS
Immuno-Oncology Program – Confirmed anti-
Differences in the microbiomes of responders
tumour activity, clinical data and sample set
and non-responders to ICI treatment have been
grown to over 3,500 patients
observed in international studies, and treatment
Microba completed multiple pre-clinical animal
model experiments for its therapeutic leads
confirming their anti-tumour activity, and
of the microbiome using faecal microbiome
transplants has demonstrated the ability to turn
ICI non-responders into responders12, 13.
demonstrating induction of a specific and targeted
Using the Company’s data-driven Therapeutic
immune response. This included a refractory
Platform, this has enabled the Company to identify
mouse model of melanoma, an ICI responsive
organisms that are commonly observed in ICI
colon adenocarcinoma MC38 syngeneic mouse
responders, but consistently deficient in ICI non-
model, and a B16-F10 mouse tumour model.
responders Subsequent pre-clinical investigation
Microba’s clinical data and sample set for this
program was grown to over 3,500 patients.
Firstly, through the national Precision Oncology
Screening Platform Enabling Clinical Trials
(PrOSPeCT) study7 where Microba is capturing a
large and diverse bank of patient specimens for
cancer patients receiving treatment and enrolled
in clinical trials. This has quickly grown to over
2,500 patient samples and is expected to be one
of these leads through both in vitro models and in
vivo animal models has demonstrated that these
organisms induce specific and targeted immune
responses, and are able to significantly reduce
tumour burden. A microbiome-based adjuvant
therapy that increases response to these drugs has
the potential to become standard of care across
a range of cancers, and therefore represents a
substantial commercial opportunity for Microba.
of the largest clinical specimen resources with
Autoimmune Disease Program – Successful
respect to the microbiome and cancer treatment.
completion of world-first discovery program
Secondly, through more than 1,000 patient
samples Microba has analysed from internally
recruited and published studies. These additional
clinical insights are expected to support the lead
candidate selection decision processes and the
pre-clinical package.
This program is targeting the development of a
therapeutic to improve response rates in cancer
patients receiving immune checkpoint inhibitor (ICI)
therapy. Global ICI sales continue to grow, with
Merck announcing sales of the market-leading drug
Keytruda of US$25b for calendar year 20238.
In June 2024, the autoimmune disease discovery
program with partner Ginkgo Bioworks (NYSE:
DNA) was successfully completed on time and
on budget with primary and secondary activity
screening data received for all lead bacterial strains.
The world-first discovery program delivered
compelling biological activity enabling selection
of 6 lead strains which demonstrate significant
disease relevant activity, generating new
therapeutic intellectual property assets for the
Company. Overall the program generated more
than 3 million data points, and the high activity
There is an increasing body of literature
hit-rate has further validated Microba’s data driven
supporting a key role for the microbiome in
therapeutic platform and valuation of the Microba
cancer . Cancer immunotherapy, and more
Therapeutic business.
9
specifically ICIs have become standard of care
for a range of tumour types. However, despite
their impact on cancer treatment, up to 70%
of patients do not respond to these drugs10, 11
leaving a large, underserved patient population.
Annual Report 2024
The data generated through the discovery
program provides strong biological validation for
further investment in these assets to move into the
next stage of development.
19
Review of Operations & Activities
THERAPEUTICS
The goal of this program is to discover and
develop novel treatments for autoimmune
diseases such as lupus, psoriatic arthritis and
certain autoimmune liver diseases. Microba’s
Autoimmune Disease program was established
in partnership with Ginkgo Bioworks (NYSE: DNA)
in FY22 following Ginkgo Biowork’s strategic
investment into Microba’s ASX IPO. Both parties
in collaboration, committed to a two-year
drug discovery program principally targeting
autoimmune disorders. The partnership brought
Biobank
Together with the Queensland University of
Technology (QUT), in June 2023 Microba was
awarded a $2.92m grant to enable development
of the Australian Human Microbiome Biobank
(AHMB). The collaborative program is aimed to
isolate and characterise thousands of new species
from the human microbiome to establish a worldleading human microbiome biobank and has
made significant progress in the past year.
together Microba’s unique ability to identify and
Initial work during FY24 has generated more
isolate human gut bacteria associated with health
than 10,000 isolates comprising over 500
together with the high-throughput microbial
species of w
Share your feedback
Discover